-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics Q3 EPS $(0.12) Misses $0.04 Estimate, Sales $5.647M Miss $29.000M Estimate

Benzinga·11/16/2026 12:16:47
Listen to the news
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 53.85 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $5.647 million which missed the analyst consensus estimate of $29.000 million by 80.53 percent. This is a 13.12 percent decrease over sales of $6.500 million the same period last year.